March 2025: The Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute Schizophrenia: Replication in Pooled Data From Two Phase 3 Trials

Dr. William Horan (Bristol Myers Squibb) joins AJP Audio to discuss a newly approved, novel treatment for schizophrenia spectrum disorder, which has potential impacts for cognition in patients.  Afterwards, AJP Editor-in-Chief Dr. Ned Kalin puts the rest of the March issue into context. 00:45     Horan interview 03:15     Novel mechanism of action in the treatment of schizophrenia 05:39     Side effect profiles 07:20     Clinical impacts 08:31     The need for further investigation 09:58     Limitations 11:05     Further research 13:08     Kalin interview 13:21     Horan et al. 17:34     Levenstein et al. 19:00     Fountoulakis et al. 20:57     Couture et al. 23:18     Stern et al. 27:35     McGirr et al. Transcript Be sure to let your colleagues know about the podcast, and please rate and review it on Apple Podcasts, Google Podcasts, Spotify, or wherever you listen to it. Subscribe to the podcast here. Listen to other podcasts produced by the American Psychiatric Association. Browse articles online. How authors may submit their work. Follow the journals of APA Publishing on Twitter. E-mail us at [email protected]

There are no comments yet.

Please log in to write the first comment.